Jasper Therapeutics, Inc. (JSPR)
0.51
+0.01
(+2.91%)
USD |
NASDAQ |
Oct 23, 16:00
0.52
+0.01
(+1.96%)
After-Hours: 20:00
Jasper Therapeutics Enterprise Value : 6.860M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 6.860M |
| October 22, 2026 | 6.455M |
| October 21, 2026 | 6.700M |
| October 20, 2026 | 6.576M |
| October 19, 2026 | 5.944M |
| October 16, 2026 | 6.014M |
| October 15, 2026 | 7.480M |
| October 14, 2026 | 6.607M |
| October 13, 2026 | 6.455M |
| October 12, 2026 | 8.123M |
| October 09, 2026 | 8.55M |
| October 08, 2026 | 8.264M |
| October 07, 2026 | 8.536M |
| October 06, 2026 | 8.266M |
| October 05, 2026 | 9.185M |
| October 02, 2026 | 8.410M |
| October 01, 2026 | 9.331M |
| September 30, 2026 | 8.825M |
| September 29, 2026 | 10.10M |
| September 28, 2026 | 10.12M |
| September 25, 2026 | 9.642M |
| September 24, 2026 | 8.977M |
| September 23, 2026 | 8.454M |
| September 22, 2026 | 10.03M |
| September 21, 2026 | 9.463M |
| Date | Value |
|---|---|
| September 18, 2026 | 9.887M |
| September 17, 2026 | 10.34M |
| September 16, 2026 | 8.850M |
| September 15, 2026 | 8.547M |
| September 14, 2026 | 10.31M |
| September 11, 2026 | 11.08M |
| September 10, 2026 | 12.21M |
| September 09, 2026 | 12.22M |
| September 08, 2026 | 12.46M |
| September 04, 2026 | 12.44M |
| September 03, 2026 | 11.81M |
| September 02, 2026 | 12.33M |
| September 01, 2026 | 12.13M |
| August 31, 2026 | 12.51M |
| August 28, 2026 | 12.19M |
| August 27, 2026 | 12.17M |
| August 26, 2026 | 12.70M |
| August 25, 2026 | 12.76M |
| August 24, 2026 | 12.82M |
| August 21, 2026 | 12.64M |
| August 20, 2026 | 11.95M |
| August 19, 2026 | 13.50M |
| August 18, 2026 | 13.60M |
| August 17, 2026 | 16.19M |
| August 14, 2026 | 14.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 534.42M |
| Amgen, Inc. | 280.78B |
| Anika Therapeutics, Inc. | 273.50M |
| BioCryst Pharmaceuticals, Inc. | 2.436B |
| Imunon, Inc. | 6.743M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.76M |
| Total Expenses (Quarterly) | 2.76M |
| EPS Diluted (Quarterly) | -0.0962 |
| Earnings Yield | -310.0% |
| Normalized Earnings Yield | -407.16 |